Patent SG-11201804003V-A (SG)
Title: Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
Inventor: BRESSLER ERIC M
IPC: G01N33/574
Filed: 2016-11-18
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - Organization International Bureau rezt.dlid (43) International Publication Date .... .....r ....) 26 May 2017(26.05.2017) WIPO I PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/087825 Publication Al Number (51) International Patent Classification: SHMUELI, Ron B.; do AsclepiX Therapeutics, LLC, 810 A61K 35/44 (2015.01) A61K 39/145 (2006.01) Wyman Park Drive, Baltimore, MD 21211 (US). A61K 38/08 (2006.01) CO7K 7/08 (2006.01) A61K 38/10 (2006.01) CO7K 14/78 (2006.01) (74) Agent: HAYMAN, Mark L.; Morgan, Lewis & Bockius A61K 38/39 (2006.01) GO1N 33/574 (2006.01) LLP, 1111 Pennsylvania Avenue, NW, Washington, DC 20004 (US). (21) International Application Number: PCT/US2016/062816 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 18 November 2016 (18.11.2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (26) Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/257,569 19 November 2015 (19.11.2015) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (71) Applicant: ASCLEPIX THERAPEUTICS, LLC. TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, [US/US]; 810 Wyman Park Drive, Baltimore, MD 21211 ZW. (US). (84) Designated States (unless otherwise indicated, for every (72) Inventors: BRESSLER, Eric M.; c/o AsclepiX Thera- kind of regional protection available): ARIPO (BW, GH, peutics, LLC, 810 Wyman Park Drive, Baltimore, MD GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 21211 (US). GREEN, Jordan J.; c/o AsclepiX Therapeut- ics, LLC, 810 Wyman Park Drive, Baltimore, MD 21211 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (US). PANDEY, Niranjan B.; c/o AsclepiX Therapeutics, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, LLC, 810 Wyman Park Drive, Baltimore, MD 21211 (US). SM, TR), OAPI BJ, CF, CG, CI, CM, GA, GN, GQ, POPEL, Aleksander S.; c/o AsclepiX Therapeutics, LLC, (BF, GW, KM, ML, MR, NE, SN, TD, TG). 810 Wyman Park Drive, Baltimore, MD 21211 (US). [Continued on next page] (54) Title: PEPTIDES WITH ANTI-ANGIOGENIC, ANTI-LYMPHANGIOGENIC, AND ANTI-EDEMIC PROPERTIES AND NANOPARTICLE FORMULATIONS Figure 1 ,, R \ , *X:, .‘‘\ a ' HOf l, ws ‘,' — • ' ‘S Ott \A a t‘‘ e\::•,:••;•;•••x <\",Azzt,, i NG.NNV•\• , ,\ ,•,. •om •,: ..~: ‘ ' ` \., P • ..,,,,„ •=.‘ Analog p.MAPK (12021Y tO •••• W 1-1 P07 .4t ' \\* ' ei QC v I - -- QC N v 0. It - -- 1-1 N (57) : The present invention in various aspects and embodiments involves pharmaceutical compositions of peptides derived from the a5 fibril of type IV collagen, and uses thereof for medical treatment. The peptides target a5(31 and avf33 integrins, and in - 0 hibit signaling through multiple receptors, and fmd use for inhibiting vascular permeability, angiogenesis, lymphangiogenesis. WO 2017/087825 Al MIDEDIMOMOIDERMEMOOMMEMBIDIOUDEMOVOIS Published: — before the expiration of the time limit for amending the — with international search report (Art. 21(3)) claims and to be republished in amendments (Rule 48.2(h)) the event of receipt of